pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·2h ago·1 min read
save

Health tech investors shift focus to larger funding rounds, Cityblock secures $116 million

Sep 3, 2026·read at Endpoints ↗DealPositive

Throughout the past year, investors in digital health have increasingly favored megafunding rounds rather than smaller seed or Series A deals.

In August, community-health startup Cityblock announced a $116 million Series round, illustrating the new scale of capital flowing into the sector.

The trend suggests that capital providers see greater upside in mature digital-health platforms, which could accelerate product development and market expansion for companies targeting integrated care solutions.

Analysts expect the shift toward larger rounds to continue as investors seek to back businesses with proven models and the potential for significant returns.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Health tech investors are looking at bigger bets”

read at Endpoints ↗
76 words · retrieved 1h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 1h agoAbbVie claims Phase 3 win for multiple myeloma drug etentamigEndpoints
  • 4h agoSummit, Akeso say ivonescimab clears OS bar in Phase 3 lung cancer trialEndpoints
  • 5h agoSuperluminal secures $60M for Phase 1 of genetic obesity drugEndpoints
  • 6h agoGSK to license Hutchmed’s KRAS-EGFR cancer drug for $110M upfrontEndpoints
  • 14h agoUltragenyx’s Angelman therapy fails Phase 3 trial in setback for company and patientsEndpoints